1

2

3
Barker Peter L, Burnier John P, Gadek Thomas, Thorsett Eugene D: Small cyclic platelet aggregation inhibitors.. Genentech, April 29, 1992: EP0482080-A1 (3 worldwide citation)

A platelet aggregation inhibitor useful as an antithrombotic is provided which consists of a synthetic cyclic pentapeptide containing the tripeptide sequence Arg-Gly-Asp and a thioether linkage in the cycle. A preferred platelet aggregation inhibitor is represented by formula (I), where R1 and R9 ar ...


4
Barker Peter L, Firestone Raymond A: Synthesis of benzofurans. Merck & Co, February 3, 1988: GB2193211-A (1 worldwide citation)

Benzofurans of the formula are produced by (A) reacting at or about reflux temperature in the presence of a strong base (pKa>/=14) and a high boiling solvent (>/=100 DEG C): wherein, R, R, R and R are hydrogen or electron releasing groups R is halogen, lower alkyl (C1-C7) sulfonate or aryl sulfonate ...


5

6
Morimoto Bruce H, Barker Peter L: Phosphocholine linked prodrug derivatives. Supergen, Morimoto Bruce H, Barker Peter L, FRANKFORT Howard M, August 24, 2000: WO/2000/048572 (1 worldwide citation)

Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) ...


7
Morimoto Bruce H, Barker Peter L: Phosphocholine linked prodrug derivatives. Supergen, December 12, 2001: EP1161226-A1

Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) ...


8
Finke Paul E, Shah Shrenik K, Hagmann William, Dorn Conrad P, Doherty James B, Barker Peter L, Firestone Raymond A: Azetidinones substitues en tant quagents anti-inflammatoires et anti-degeneratifs, Substituted azetidinones as anti-inflammatory antidegenerative agents. Merck &Amp Co, GOWLING LAFLEUR HENDERSON, January 23, 1996: CA1337990

New substituted azetidinones of Formula I are found aspotent elastase inhibitors and thereby useful anti-inflammatory and anti-degenerative agents Image (I) The active substituted azetidinones can be used toprovide pharmaceutical compositions as proteaseinhibitors useful for controlling tissue damag ...


9
Barker Peter L, Burnier John P, Lazarus Robert A: Cyclic peptides containing arg-gly-asp flanked by proline. Genentech, sWINTER Daryl B, August 8, 1991: WO/1991/011458

A small cyclic peptide is provided having high affinity for the platelet GP II¿b?III¿a? receptor, which peptide is represented by formula $g(a) where R¿1? and R¿4? are from 0 to 4 amino acids, R¿3? is from 1 to 4 amino acids; R¿2? is -CH¿2?CO- or from 1 to 4 amino acids; Xaa¿8? may be Met, Phe, nLeu ...


10
Barker Peter L, Burnier John P, Gadek Thomas, Thorsett Eugene D: Small cyclic platelet aggregation inhibitors. Genentech, Barker Peter L, Burnier John P, Gadek Thomas, Thorsett Eugene D, sWINTER Daryl B, February 7, 1991: WO/1991/001331

A platelet aggregation inhibitor useful as an antithrombotic is provided which consists of a synthetic cyclic pentapeptide containing the tripeptide sequence Arg-Gly-Asp and a thioether linkage in the cycle. A preferred platelet aggregation inhibitor is represented by formula (I), where R¿1? and R¿9 ...



Click the thumbnails below to visualize the patent trend.